TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05734729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFFIDRAIN
Description: . Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EFFIDRAIN
Description: . Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual drainage system
Description: drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual drainage system
Description: drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
Study: NCT05236998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903 (FDC)
Description: Single oral administration of SID1903 (FDC) after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903 (FDC)
Description: Single oral administration of SID1903 (FDC) after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Sitagliptin
Description: Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Sitagliptin
Description: Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Study: NCT05572463

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sintilimab + IBI110
Description: IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
Study: NCT06348563

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AGED Multiple Target Assay in Healthy Controls
Description: Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to healthy controls

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AGED Multiple Target Assay in NAFLD Participants
Description: Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to NAFLD participants (defined as simple steatosis through NASH)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AGED Multiple Target Assay in Fibrosis Participants
Description: Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to liver fibrosis stage (F0-F4)
Study: NCT06061198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a virtual reality device
Description: the patient will wear a masque tht will provide a virtual reality experience using a VR Gear connected to a mobile phone through an application installed on the mobile phone
Study: NCT05158634

Intervention type: OTHER
Intervention: Evaluations
Description: Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)
Study: NCT05344833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
Study: NCT06238622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study: NCT05107869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Saturated Fat
Description: High saturated fat meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Saturated Fat
Description: High saturated fat meal
Study: NCT05859477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360 mg, i.v., every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m², i.v., day 1, every 3 weeks
Study: NCT05520528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia
Description: The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
Study: NCT05087537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Valve ablation
Description: Valve ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Valve ablation and bladder neck incision
Description: Valve ablation and bladder neck incision
Study: NCT01132105

Intervention type: DEVICE
Intervention: Vestibular myogenic evoked potential analyzer
Study: NCT05891054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active breaks
Description: Two active breaks are taken daily in a predetermined time slot. The development of each break is done through access to a specific digital platform where students follow the instructions of an avatar, which is in charge of guiding the realization of the active break. Each active rest involves a total of 4 minutes of activity, in which two sets of 20 seconds of work and 10 seconds of rest of four different exercises are performed, ending with a brief return to calm consisting of two deep breaths. The activities selected for each of the active breaks include aerobic and strengthening activities of moderate and vigorous intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physically active learning
Description: The physically active learning is carried out once a week for 1 hour outside the classroom, where physical activity (through movement, jumping, strengthening exercises, throwing, etc.) is incorporated into academic mathematics classes.~The mathematics teachers (with the support of the research team) are in charge of teaching the physically active classes. Prior to the development of each class, the research team, together with the mathematics teachers involved, meet and design the class according to the contents to be addressed.
Study: NCT06312891

Intervention type: DRUG
Intervention: Ivabradine
Description: heart rate lowering therapy
Study: NCT05191160

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy Milk
Description: 250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's Milk
Description: 250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Sweetened Beverages
Description: 355 mL, single-serve cans 130-140 Kcal, 0g of protein
Study: NCT05809934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: AZD2693 solution SC once per month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: AZD2693 solution SC once per month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% solution SC once per month
Study: NCT06444529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraclonidine Hydrochloride Ophthalmic Solution
Description: Investigational ophthalmic solution applied topically to the eye with a dropper bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
Study: NCT03883139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JASPER
Description: JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
Study: NCT05512871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)
Description: The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)
Description: The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
Study: NCT05222633

Intervention type: DRUG
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.05ml intravitreal injection
Study: NCT03883139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTT (Discrete Trial Training)
Description: DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction.
Study: NCT05067764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aponeurectomy with grafting
Description: The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.~The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aponeurectomy alone
Description: The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.
Study: NCT05222633

Intervention type: DRUG
Intervention: Aflibercept
Description: Aflibercept 2.0mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Aflibercept
Description: Aflibercept 2.0mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Aflibercept
Description: Aflibercept 2.0mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Aflibercept
Description: Aflibercept 2.0mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Conbercept
Description: Conbercept 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Conbercept
Description: Conbercept 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Conbercept
Description: Conbercept 0.5mg/0.05ml intravitreal injection

Intervention type: DRUG
Intervention: Conbercept
Description: Conbercept 0.5mg/0.05ml intravitreal injection
Study: NCT05587751

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Pulmonary function test to measure lung function

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plethysmography
Description: Pulmonary function test to measure lung volume
Study: NCT05456425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001
Description: CBT-001 eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-001
Description: CBT-001 eye drop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Formulation without drug
Study: NCT04622943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: firearms safety
Description: interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition
Description: interactive and engaging website with videos and educational games to teach children about nutrition and exercise
Study: NCT05034822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib 1.5% cream applied twice daily.
Study: NCT06350383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WINGS+PM+
Description: WINGS+PM+ is a safety, harm reduction, and brief psychological intervention combined and adapted by community members from informal settlements in Kenya (IPV survivors, health clinic staff, and CHVs) from two evidence-based interventions: Wings of Hope (WINGS) and Problem Management Plus (PM+). This intervention was designed to be facilitated by non-specialists (e.g., CHVs). It involves seven 90-minute weekly sessions. The intervention is informed by social cognitive theory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PM+-only
Description: PM+: is a brief psychological intervention also designed to be facilitated by non-specialists (e.g. CHVs) and focused on problem management and evidence-based behavioral strategies to enhance one's capacity to adaptively manage psychological distress. It has been shown to be effective at reducing psychological distress among women who have experienced gender-based violence in informal settlements in Nairobi, Kenya. PM+ involves five 90-minute, weekly individual sessions.
Study: NCT05030688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study: NCT05149170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
Study: NCT03587532

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Description: ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hemodynamic evaluation
Description: Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biological and pathological markers of ischemia
Description: * Systemic and local capillary lactate on blood samples~* Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~* Pathological analyses of the biopsies at 3 ROI
Study: NCT05401266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mild hypercapnia
Description: Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
Study: NCT04981613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kunxian capsule
Description: Kunxian capsule (2# tid or 2# bid) + irbesartan tablet (150mg qd or 300mg qd) for 48 weeks
Study: NCT05919706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education with Game-Based Mobile Technology and Motivational Interviewing
Description: Education program, game-based mobile technology and motivational interview were applied to the patients in the experimental group. The patients' self-management, quality of life, and satisfaction level scores for the intervention were determined.
Study: NCT03899701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC I and PEC II blocks
Description: Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
Study: NCT06496373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized tumor preventive vaccines
Description: Personalised mRNA vaccine combined with PD-1 inhibitor treatment every 3 weeks, 3 weeks as a treatment cycle, a total of 13 cycles.
Study: NCT05299073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB09
Description: Single dose of 35mg SC administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Xgeva
Description: Single dose of 35mg SC administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Xgeva
Description: Single dose of 35mg SC administered
Study: NCT05587283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Low dose LABTHERA-001 capsule
Description: Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Medium dose LABTHERA-001 capsule
Description: Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: High dose LABTHERA-001 capsule
Description: High dose LABTHERA-001 capsule, 5 x 10\^9 CFU/capsule with excipients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Low dose Placebo capsule
Description: Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Medium dose Placebo capsule
Description: Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: High dose Placebo capsule
Description: High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
Study: NCT04958538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
Study: NCT06087757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Clemastine with a blinded randomize withdrawal
Description: Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Clemastine with a blinded randomize withdrawal
Description: Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.